anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Stavudine
Trial phase: Phase 4
ATC code: J05AF04 | J05AR07
SMILES: Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: 50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test

1.5 microns at 50mg: STAG generated monodisperse 1.5micron particles
Eligibility criteria:
Inclusion Criteria:

Male or females aged greater than 18 years with a documented history of reversible airways disease responding to beta2-adrenergic therapy.
Asthmatic patients who are free from significant cardiac, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease.
Patients who are stabilized on 500 micrograms or less of inhaled beclomethasone dipropionate or alternative inhaled corticosteroid (budesonide or ciclesonide).
Patients who are able and willing to give written informed consent to take part in the study
Not taking any regular medication that is contraindicated in those about to receive fluitcasone propionate (as indicated in the British National Formularly); other than the oral contraceptive pill.

Exclusion Criteria:

Those requiring maintenance oral or parenteral corticosteroid therapy for their airways disease or patients who have ceased maintenance oral or parenteral corticosteroid therapy within the four weeks prior to visit 1
Those requiring greater than 500 micrograms of inhaled beclomethasone dipropionate or alternative inhaled corticosteroid (budesonide or ciclesonide).
Subjects that have received inhaled or intravenous fluticasone propionate in the last 2 months.
Those whose reversible airways obstruction has been unstable in the last four weeks (indicated by any change in their maintenance therapy).
Those participants who have had a lower respiratory tract infection in the previous four weeks
Those who have donated 450ml blood or more within the previous 1 month.
Those who have a history of drug allergy which, in the opinion of the Unit Physician, contraindicates his/her participation in the study.
Any female volunteer or females who are pregnant or lactating or are likely to become pregnant during the trial. Women of child-bearing potential may be included in the study if, in the opinion of the investigator, they are taking adequate contraceptive precautions.
Participants with a known or suspected allergy to corticosteroids or any component of the formulations and/or Suspected hypersensitivity to inhaled corticosteroid (this will be asked directly at the screening visit).
Any patient with a contraindication to taking an inhaled steroid and specifically FP, listed in the British National Formulary will not be entered into this study
Those who have experienced an acute asthma exacerbation requiring emergency room treatment and/or hospitalisation within one month of visit 1.
Intervention: Stavudine
Trial phase: Phase 4
ATC code: J05AF04 | J05AR07
SMILES: Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: 50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test

6 microns at 50mg: STAG generated monodisperse 6 micron particles
Eligibility criteria:
Inclusion Criteria:

Male or females aged greater than 18 years with a documented history of reversible airways disease responding to beta2-adrenergic therapy.
Asthmatic patients who are free from significant cardiac, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease.
Patients who are stabilized on 500 micrograms or less of inhaled beclomethasone dipropionate or alternative inhaled corticosteroid (budesonide or ciclesonide).
Patients who are able and willing to give written informed consent to take part in the study
Not taking any regular medication that is contraindicated in those about to receive fluitcasone propionate (as indicated in the British National Formularly); other than the oral contraceptive pill.

Exclusion Criteria:

Those requiring maintenance oral or parenteral corticosteroid therapy for their airways disease or patients who have ceased maintenance oral or parenteral corticosteroid therapy within the four weeks prior to visit 1
Those requiring greater than 500 micrograms of inhaled beclomethasone dipropionate or alternative inhaled corticosteroid (budesonide or ciclesonide).
Subjects that have received inhaled or intravenous fluticasone propionate in the last 2 months.
Those whose reversible airways obstruction has been unstable in the last four weeks (indicated by any change in their maintenance therapy).
Those participants who have had a lower respiratory tract infection in the previous four weeks
Those who have donated 450ml blood or more within the previous 1 month.
Those who have a history of drug allergy which, in the opinion of the Unit Physician, contraindicates his/her participation in the study.
Any female volunteer or females who are pregnant or lactating or are likely to become pregnant during the trial. Women of child-bearing potential may be included in the study if, in the opinion of the investigator, they are taking adequate contraceptive precautions.
Participants with a known or suspected allergy to corticosteroids or any component of the formulations and/or Suspected hypersensitivity to inhaled corticosteroid (this will be asked directly at the screening visit).
Any patient with a contraindication to taking an inhaled steroid and specifically FP, listed in the British National Formulary will not be entered into this study
Those who have experienced an acute asthma exacerbation requiring emergency room treatment and/or hospitalisation within one month of visit 1.
Intervention: Rifaximin
Trial phase: Phase 3
ATC code: A07AA11 | D06AX11
SMILES: COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Subjects in the case group were in the study for 3 months.

Rifaximin: All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment did not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
Eligibility criteria:
Inclusion criteria: Parkinson's Disease

Exclusion Criteria:

Wheelchair-bound, akinetic individuals
Tube-fed individuals
Presence of dementia
Unwilling or unable to complete the tests
Allergic or intolerant to rifaximin
Presence of chronic upper or lower gastrointestinal disorders that have symptoms that may be confused with SBBO (e.g., irritable bowel syndrome, inflammatory bowel disease, celiac disease, functional dyspepsia, gastroparesis, and chronic pancreatitis)
Presence of prior surgery on the gastrointestinal tract except cholecystectomy, appendectomy or herniorrhaphy
Presence of severe concomitant acute or chronic medical condition that may interfere with the completion or interpretation of the test results
Women of childbearing potential. Given the age of patients with Parkinson's disease, we do not anticipate this being a large population.
Use of antibiotics within 1 month of breath testing
Intervention: Azathioprine
Trial phase: Phase 3
ATC code: L04AX01
SMILES: Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: Participants were administered induction therapy (corticosteroids and either cyclophosphamide or rituximab) in the 6 months leading up to randomization. After randomization, participants were administered belimumab 10 mg/kg intravenously over 1 hour, at Day 0, 14, 28 and every 28 days thereafter until 12 months after the last subject was randomized. All participants received oral azathioprine at a target dose of 2 mg/kg/day. In Belgium-only open-label extension, all participants received belimumab 10 mg/kg every 28 days until Week 24, with a final evaluation at Week 28.
Eligibility criteria:
Key Inclusion Criteria:

Clinical diagnosis Wegener's granulomatosis or microscopic polyangiitis by Chapel Hill criteria.
Disease flare in the past 26 weeks requiring treatment with high dose corticosteroids and 1 of the following medications: rituximab, oral cyclophosphamide OR IV cyclophosphamide.
Tested positive for anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibodies at any time prior to enrollment.
Achieve remission no more than 26 weeks after first dose of induction treatment. Remission is defined as a Birmingham Vasculitis Activity (BVAS) score of 0 and receiving less than 10 mg/day of oral prednisone (or equivalent) on 2 consecutive visits 21 to 35 days apart.
Maintenance therapy on this study must start no more than 2 weeks after confirmation of remission.

Key Exclusion Criteria:

Pregnant or nursing.
Receipt of a B cell targeted therapy (other than rituximab) at anytime
Receipt of an investigational biological agent within the past 60 days.
Required management of acute or chronic infections within the past 60 days.
Current drug or alcohol abuse or dependence.
Current or past positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
History of severe allergic reaction to contrast agents or biological medicines.
Intervention: Bimatoprost
Trial phase: Phase 4
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 49
Group description: One drop to the study eye(s) once a day in the evening for 6 months
Eligibility criteria:
Inclusion Criteria:

Diagnosed with either open-angle glaucoma or ocular hypertension in at least one eye and be treatment naïve to any glaucoma treatment.
Intraocular pressure (IOP) between 19 mmHg and 35 mmHg in at least one eye, which would be the study eye.
IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
Able to follow instructions and be willing and able to attend all study visits.
Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye.
Must read, sign, and date an Ethics Committee-approved informed consent form.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Known medical history of allergy, hypersensitivity or poor tolerance to any components of the study medications to be used in this study that is deemed clinically significant in the opinion of the Principal Investigator.
Any abnormality preventing reliable applanation tonometry in either eye.
Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
Prior treatment of dry eye with punctal plugs, punctal cautery, Restasis® or topical ocular corticosteroids.
History of ocular surface disease (dry eye) or current/prior use of dry eye medications (either over-the counter or prescription medications).
Contact lens wear.
Intraocular conventional surgery or laser surgery in either eye that is less than three months prior to the Screening Visit.
Use of any systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for at least 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study.
Women of childbearing potential not using reliable means of birth control, are pregnant, or lactating.
Unwilling to risk the possibility of darkened iris or eyelash changes.
Participation in any other investigational study within 30 days prior to the Screening Visit.
Other protocol-defined exclusion criteria may apply.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 67
Group description: If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.

Normal Saline: Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
Eligibility criteria:
Inclusion Criteria:

Nulliparous and multiparous women ages 18-50, who are English or Spanish speaking, who present for intrauterine device placement for contraception or menorrhagia (in the case of Mirena IUD insertion).

Exclusion Criteria:

Pregnancy
Any diagnosed chronic pain issues (i.e. fibromyalgia, endometriosis, dysmenorrhea, irritable bowel syndrome, interstitial cystitis)
If the patient has taken any pain medications within 6 hours of enrollment, including aspirin or other NSAIDs
Misoprostol administration within 24 hours of enrollment
History of prior IUD insertion
Known allergy to NSAIDs including diagnosis of aspirin or NSAID induced asthma or urticaria

Known contraindications to NSAIDs, such as the following medications that are risk category D (consider therapy modification) or X (avoid combination) including

bile acid sequestrants (D - may decrease absorption of NSAIDs)
cyclosporine (D - NSAIDs may enhance the nephrotoxic effects)
drotrecogin alfa (D - NSAIDs may enhance the adverse/toxic effects, cause bleeding)
floctafenine (X - may enhance adverse/toxic effect of NSAIDs)
lithium (D - NSAIDs may decrease serum concentration)
methotrexate (D - NSAIDs may decrease excretion)
pentoxifylline (X - Ketorolac may enhance adverse/toxic effects)
probenecid (X - may increase serum concentration of Ketorolac)
rivaroxaban (D - Anti-platelet drugs may enhance anti-coagulation effect)
SSRIs (D - may enhance the anti-platelet effect of NSAIDs, NSAIDs may diminish the therapeutic effect of SSRIs)
warfarin (D - NSAIDs may enhance the anti-coagulation effect)
Renal insufficiency (by history and/or chart review)
Peptic ulcer disease or history of significant gastrointestinal bleeding
Known thrombocytopenia, known coagulopathy, or known bleeding disorder
Known contraindications to IUD
Intervention: Ketorolac
Trial phase: Not Applicable
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 67
Group description: If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.

Ketorolac: Ketorolac 30mg intramuscular injection, 1cc volume
Eligibility criteria:
Inclusion Criteria:

Nulliparous and multiparous women ages 18-50, who are English or Spanish speaking, who present for intrauterine device placement for contraception or menorrhagia (in the case of Mirena IUD insertion).

Exclusion Criteria:

Pregnancy
Any diagnosed chronic pain issues (i.e. fibromyalgia, endometriosis, dysmenorrhea, irritable bowel syndrome, interstitial cystitis)
If the patient has taken any pain medications within 6 hours of enrollment, including aspirin or other NSAIDs
Misoprostol administration within 24 hours of enrollment
History of prior IUD insertion
Known allergy to NSAIDs including diagnosis of aspirin or NSAID induced asthma or urticaria

Known contraindications to NSAIDs, such as the following medications that are risk category D (consider therapy modification) or X (avoid combination) including

bile acid sequestrants (D - may decrease absorption of NSAIDs)
cyclosporine (D - NSAIDs may enhance the nephrotoxic effects)
drotrecogin alfa (D - NSAIDs may enhance the adverse/toxic effects, cause bleeding)
floctafenine (X - may enhance adverse/toxic effect of NSAIDs)
lithium (D - NSAIDs may decrease serum concentration)
methotrexate (D - NSAIDs may decrease excretion)
pentoxifylline (X - Ketorolac may enhance adverse/toxic effects)
probenecid (X - may increase serum concentration of Ketorolac)
rivaroxaban (D - Anti-platelet drugs may enhance anti-coagulation effect)
SSRIs (D - may enhance the anti-platelet effect of NSAIDs, NSAIDs may diminish the therapeutic effect of SSRIs)
warfarin (D - NSAIDs may enhance the anti-coagulation effect)
Renal insufficiency (by history and/or chart review)
Peptic ulcer disease or history of significant gastrointestinal bleeding
Known thrombocytopenia, known coagulopathy, or known bleeding disorder
Known contraindications to IUD
Intervention: (+)-Nicotine (+)-di-p-toluoyl tartrate
Trial phase: Phase 4
SMILES: CN1CCCC1c1cccnc1.Cc1ccc(C(=O)OC(C(=O)O)C(OC(=O)c2ccc(C)cc2)C(=O)O)cc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 127
Group description: 21 mg nicotine patch

Nicotine patch - transdermal
Eligibility criteria:
Inclusion Criteria:

21 - 60 years old
must meet DSM-IV criteria for nicotine dependence and be actively smoking

Exclusion Criteria: subjects must meet study guidelines for medical and mental health status.
Intervention: CHOP regimen
Trial phase: Phase 4
SMILES: CC12C=CC(=O)C=C1CCC1C2C(=O)CC2(C)C1CCC2(O)C(=O)CO.CCC1(O)CC2CN(CCc3c([nH]c4ccccc34)C(C(=O)OC)(c3ccc4c(c3OC)N(C=O)C3C(O)(C(=O)OC)C(OC(C)=O)C5(CC)C=CCN6CCC43C65)C2)C1.COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)CC(O)(C(=O)CO)CC3OC1CC(N)C(O)C(C)O1.O=P1(N(CCCl)CCCl)NCCCO1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen

CHOP regimen: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Eligibility criteria:
Inclusion Criteria:

Age range 14-70 years old; ECOG performance status 0-2; Estimated survival time > 3 months Histological confirmed Peripheral T cell lymphoma None of chemotherapy or radiotherapy has been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test of women at reproductive age must be negative Patients could be followed up None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments.

volunteers who signed informed consent.

Exclusion Criteria:

Disagreement on blood sample collection Patients allergic of any of drug in this regimen or with metabolic disorder Pregnant or lactating women Serious medical illness likely to interfere with participation Serious infection Primitive or secondary tumors of central nervous system Chemotherapy or radiotherapy contraindication The evidence of CNS metastasis History of peripheral nervous disorder or dysphrenia patients participating in other clinical trials patients taking other antitumor drugs patients estimated to be unsuitable by investigato
Intervention: Nebivolol
Trial phase: Phase 4
ATC code: C07AB12 | C07BB12 | C07FB12 | C09DX05
SMILES: OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.

Nebivolol: Patient to start nebivolol and have repeat testing in 3 months
Eligibility criteria:
Inclusion Criteria:

women between the ages of 40-80
with evidence of coronary microvascular dysfunction as determined by the presence of rest and or exertional chest tightness and a history of either an elevated troponin level or positive stress test ( EKG criteria or imaging) , as well as non-obstructive coronary artery disease (<50% epicardial obstruction) by either diagnostic catheterization with coronary angiography or CT angiography.

Exclusion Criteria:

Women who cannot tolerate a beta blocker.
Women receiving Hormone Replacement Therapy
Women of child-bearing age who are not on a birth-control method.
Women with inability to exercise.
Women with left ventricular systolic dysfunction (LVEF less than 40%)
Women who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.
Women with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included.
Women who are unable to speak, read, and understand English and are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.
Women with any contraindications to beta blocker therapy
Women with myocardial bridging
Women with Prinzmetal's angina
Intervention: Testosterone
Trial phase: Phase 3
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 180
Group description: Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.

Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion.
Eligibility criteria:
Inclusion Criteria:

Males between 18-75 years of age
Two screening serum testosterone values less than 300 ng/dL
One or more symptoms of testosterone deficiency

Exclusion Criteria:

Previous use of the investigational product
Use of any investigational product within 30 days prior to screening and during the study
BMI less than 18 kg/m^2 or more than 35 kg/m^2
Prostatic mass(es)
Generalized skin irritation or skin disease
Lower urinary tract obstruction
Myocardial infarction or cerebrovascular accident in the last 6 months
Unstable angina or congestive heart failure
Thromboembolic disorders
Sleep apnea
Hyperparathyroidism or uncontrolled diabetes
Untreated moderate to severe depression
History of testicular, prostate, or breast cancer
HIV, Hepatitis B, or Hepatitis C positive
PSA more or equal to 3 ng/mL
Use of any medications that could be considered anabolic
Use of estrogens, Gonadotropin Releasing Hormone agonists/antagonists, antiandrogens, or human Growth Hormone
Chronic use of any drug of abuse
Involvement in a sport in which there is a screening for anabolic steroids
Not willing to use adequate contraception during the study
Partner is pregnant and/or breast feeding
Partner has a history of breast, uterine or ovarian cancer